Company Overview and News

1
Ta-Rough

2018-08-16 seekingalpha - 1
You can say whatever you want about tariffs and the pros and cons on both sides of the argument, but with respect to the metals and mining companies, keep your 'pros' to yourself. The group has been stuck in a downtrend ever since the topic of tariffs first came up, and it's now basically in full flush mode.
CENX

 
CENX / Century Aluminum Co. 10-Q Q2 2018 (Quarterly Report)

2018-08-08 sec.gov
Document UNITED STATES
CENX

 
CENX / Century Aluminum Co. IRAN NOTICE - Q2 2018

2018-08-08 sec.gov
Document August 8, 2018
CENX

8
How Much Is Alcoa Hurt By Trump Tariffs?

2018-07-21 investorplace
While Donald Trump’s tariffs are still in the early phases, we are already seeing the winners and losers. Just look at Alcoa (NYSE:AA). This week, the shares got crushed because of a dicey earnings report — largely due to the ill-effects of tariffs. On the news, AA stock fell by 13%. In fact, for the year so far, the return is -23%.
CSTM CENX ARNC AA

15
Craig Conti Named Executive Vice President and Chief Financial Officer of Century Aluminum

2018-07-16 globenewswire
CHICAGO, July 16, 2018 (GLOBE NEWSWIRE) -- Century Aluminum Company (NASDAQ:CENX) announced today that it has hired Craig C. Conti as Executive Vice President and Chief Financial Officer. Mr. Conti will join the Company on July 30, 2018 and will report directly to Century’s Chief Executive Officer. He is presently Corporate Vice President of Financial Planning and Analysis of Illinois Tool Works (ITW) and previously served as Chief Financial Officer of ITW’s welding segment.
GEC GE ITW CENX GNE

 
Century Aluminum Sets Date for Second Quarter 2018 Earnings Announcement

2018-07-11 globenewswire
CHICAGO, July 11, 2018 (GLOBE NEWSWIRE) -- Century Aluminum Company (NASDAQ:CENX) will report second quarter 2018 earnings on Wednesday, August 1, 2018 after the close of market trading. The news release will be issued through GlobeNewswire.
CENX

1
Why Goldman Sachs Is Pounding the Table for Investors to Buy Commodities for the Rest of 2018

2018-07-05 247wallst
If there is one brokerage and investment banking firm whose views can influence investors’ decisions about issues large and small, Goldman Sachs likely fits that bill. After all, its focus is on the top money management institutions and on the wealthiest investors in the world. After a serious rut, now the Goldman Sachs Commodities Research is telling customers that it’s time to buy commodities.
O87 CENX GDX BGEPF BG GLD NUE

132
5 of the Best Stocks to Invest In Right Now For Massive Growth | InvestorPlace

2018-06-29 investorplace
Investors looking for the best stocks to invest in right now often look first to the price-to-earnings (P/E) ratio to find reasonably-priced stocks. And while that might lead to a reasonably-priced stock, that offers no visibility on growth.
AMZN RSPP LTM DVN CENX JAG AA

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 156431108